Home Overview Press Room Blog Publications For Students about us
Search

About Biopolitics, Parties, Pundits & Human Biotechnology


Policy decisions about human biotechnologies have typically been debated among elite commissions and experts. But controversy is increasingly spilling over into mainstream news media and political debates.

This trend has been most notable in the United States, with the emergence of human embryonic stem cell research as a political issue. Stem cell debates at the policy level have made this discussion far more visible to the public.

The Bush Administration's restrictions on federal funding for human embryonic stem cell research elevated the issue to the front pages of newspapers. Shortly after its announcement in 2001, partisan battle lines were drawn in ways that mirror the abortion rights divide.

Republicans hoped that opposition to research that destroys embryos would increase support among their party's religious conservative base. Democrats countered by assembling a coalition of patient advocates, biomedical researchers, and biotechnology entrepreneurs and appealed to moderate swing voters and Republicans who they believed would be swayed by promises of cures.

There were some notable exceptions to this partisan line-up. Some conservatives support embryonic stem cell research; some liberals and progressives who support the research in principle criticize aspects of its conduct and regulation. Unfortunately, the polarized debate has frequently distorted facts while obscuring a range of important social issues unrelated to the moral status of embryos.



Setting the record straightby Martin H. JohnsonReproductive BioMedicine Online EditorialDecember 1st, 2016A report aiming to set the record straight after some shoddy scientific journalism on mitochondrial transfer.
“3-Parent Baby” Procedure Faces New Hurdleby Karen WeintraubScientific AmericanNovember 30th, 2016Mitochondrial disease can somehow creep back in, even if a mother’s mitochondria are virtually eliminated in an attempt to block inherited illnesses.
Human Gene Editing: A Timeline of CRISPR Cover StoriesWith recent gene editing tools, a number of high-profile media are featuring CRISPR on their covers and front pages. We gather highlights since early 2015, along with opinion polls, TV shows, and editorial board statements.
What’s behind those billion-dollar biotech deals? Often, a whole lot of hypeby Damian GardeSTATNovember 28th, 2016New deals paid out with “biobucks” which only pay out when an experimental drug hits various milestones along the path to commercialization.
'No solid evidence' for IVF add-on successby Deborah CohenBBC PanoramaNovember 28th, 2016Year-long Oxford study finds that nearly all costly add-on treatments offered by UK fertility clinics are unreliable, misleading, and risky.
Should We Rewrite the Human Genome?by Alex HardingXconomyNovember 28th, 2016Conversations of such endeavors raise ethical concerns of oversight in its research and medical applications.
Review of Blame: A Novelby Abby Lippman, Biopolitical Times guest contributorNovember 28th, 2016Blame is especially important for those unfamiliar with the range of ethical, social, legal, and political issues raised by applications of what is learned in a lab. While a work of fiction, it is definitely not science-fiction
Cambodia charges Australian nurse for running surrogacy clinicby Prak Chan ThulReutersNovember 21st, 2016As many South Asian countries take steps to clamp down on practices of commercial surrogacy tourism, stakeholders like Davis-Charles are confronted with charges.
Obama’s Science Advisors Are Worried About Future CRISPR Terrorismby Daniel OberhausVICE MotherboardNovember 21st, 2016PCAST warn that under current legislation, there is no room for rapid response to threats and misuse, recommending improved biosurveillance as a solution.
Why the Deaf Community Fears President Trumpby Sara NovicVICENovember 18th, 2016The new administration may potentially resurface the eugenics movement and erase the public safety net that has taken decades to build.
Displaying 1-10 of 1518  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760